Key result
The NOS3 Glu298Asp variant was not associated with coronary artery disease (OR 1.15; 95% CI 0.86-1.54; P=0.33) or lipid levels, but had a strong association with blood pressure.
Why the study?
Does the NOS3 Glu298Asp variant associate with CAD, blood pressure, and lipid levels in Pakistani subjects?
Case-Control (n=636)
Does the NOS3 Glu298Asp variant associate with CAD, blood pressure, and lipid levels in Pakistani subjects?
Answers are grounded in this paper and cite their sources.
The NOS3 Glu298Asp variant is not associated with CAD or lipid profiles in Pakistani subjects but shows a strong association with blood pressure.
Nitric oxide is an important antiatherosclerotic agent. The main determinant of nitric oxide levels is enzyme nitric oxide synthase encoded by the NOS3 gene, the common variants in this gene may be responsible for variations in plasma enzyme levels. The association of NOS3 variants with coronary artery disease (CAD) varies in different ethnicities. The current study aimed to determine the association of NOS3 Glu298Asp (rs1799983) with CAD and blood lipid levels in Pakistani subjects. Six hundred thirty-six samples (412 cases, 224 controls) were genotyped by TaqMan allelic discrimination assay and serum total cholesterol, and High Density Lipoprotein cholesterol (HDL-C)/Low Density Lipoprotein cholesterol (LDL-C) and triglycerides were measured. The genotype frequency was Glu/Glu = 64.6%, Glu/Asp = 30.1%, and Asp/Asp = 5.3% in cases, and Glu/Glu = 68.8%, Glu/Asp = 26.7%, and Asp/Asp = 4.5% in controls. The Asp298 (T) frequency was not significantly higher in cases than controls (20.4% vs 17.9%, P = 0.28) and risk allele was not associated with CAD (OR 1.15 (0.86–1.54), P = 0.33) and the tested lipid traits but had a strong association with blood pressure (for systolic and diastolic P = 1.9×10−–56 and 4×10−–40, respectively). In conclusion, although Glu298Asp did not show association with CAD and lipid profile in the studied cohort, it may exert its effect through blood pressure; however, the mechanism of this effect needs to be explored in the future.
No takes yet. Share an insight, caveat, or question.
Saleem Ullah Shahid (2017) conducted a case-control in Coronary Artery Disease (n=636). NOS3 Glu298Asp (rs1799983) variant vs. Controls was evaluated on Coronary artery disease (OR 1.15, 95% CI 0.86-1.54, p=0.33). The NOS3 Glu298Asp variant was not associated with coronary artery disease (OR 1.15; 95% CI 0.86-1.54; P=0.33) or lipid levels, but had a strong association with blood pressure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: